United Therapeutics price target lowered to $315 from $321 at BofA

BofA lowered the firm’s price target on United Therapeutics (UTHR) (UHTR) to $315 from $321 and keeps a Neutral rating on the shares. The firm updated its pulmonary arterial hypertension/ILD market model to reflect strong Phase 2 clinical data reported by Insmed’s (INSM) treprostinil palmitil inhalation powder — inhaled prostanoid — in PAH. In BofA’s market model, the firm had prior assumed 15%-20% inhaled prostanoid share for innovative disrupter starting in 2030 and based on the update, it increased that share to 40% peak. While the data could warrant higher TPIP adoption rates, BofA believes that step-up is warranted post-Phase 3. For United Therapeutics, competitor data looks priced into shares and risk balanced by pipeline updates.